A nanogenetic approach to genome editing
Soultana Konstantinidou a, Tiziana Schmidt a, Elena Landi a, Francesco Nocilla a, Alessandro De Carli b, Dariusz Witt c, Agnieszka Lindstaedt c, Marta D'Amora d, Michele Lai b, Giulia Freer b, Mauro Pistello b, Luciana Dente a, Arnoud Everhardt e, Francesco Tantussi d, Francesco Fuso f, Chiara Gabellini a, Piotr Barski c, Vittoria Raffa a
a Department of Biology, University of Pisa, SS12 Abetone e Brennero 4 , 56127 Pisa, Italy
b Department of Medicine, University of Pisa, SS12 Abetone e Brennero 4, 56127 Pisa, Italy
c ProChimia Surfaces, Al Zwycięstwa 96/98, 81-451 Gdynia, Poland
d Plasmon Nanotechnologies, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy
e LioniX International, P.O. Box 456, Enschede 7500 AL, The Netherlands
f Department of Physics, University of Pisa, Largo Bruno Montecorvo 3 , 56127 Pisa, Italy
Proceedings of Advanced materials and devices for nanomedicine (AMA4MED)
VALÈNCIA, Spain, 2022 May 3rd - 4th
Organizers: Claudia Tortiglione and María Moros
Invited Speaker, Vittoria Raffa, presentation 002
DOI: https://doi.org/10.29363/nanoge.amamed.2022.002
Publication date: 22nd April 2022

The CRISPR/Cas9 has revolutionized not only the process of gene editing but also  the way of understanding research. Now, we have the tools to theoretically modify the genetics of potentially any organism for industrial, biotechnological, and medical applications. Regarding the latter one, novel therapies are being developed aiming to directly intervene to the genome and treat previously incurable diseases. Despite this scenario is moving faster and getting closer towards a reality, it might not be true yet due to the unresolved issues related to delivery and safety. To help with this, nanomedicine and synthetic biology are emerging with cutting-edge solutions and new perspectives to overcome the above mentioned limitations, as for instance, controlled delivery and remote spatio-temporal activation of gene editing. Here, we propose a nano-formulation of Cas9 consisting of the Cas9 enzyme conjugated to a gold nanoparticle (AuNP-Cas9). Our results showed high cleavage and gene editing efficiency in vitro, and zebrafish embryos, respectively, and the ability to spontaneously localize in the nucleus of human melanoma cells. Thanks to the plasmonic properties of gold nanoparticles, this nano-formulation serves as a nano-source of heat validated in zebrafish embryos and could consequently combine efficient gene editing with targeted photothermal therapy in cells.

The presented project is part of the I-GENE project, which is funded by Horizon 2020, Call identifier: H2020-FETOPEN-2018-2020

© FUNDACIO DE LA COMUNITAT VALENCIANA SCITO
We use our own and third party cookies for analysing and measuring usage of our website to improve our services. If you continue browsing, we consider accepting its use. You can check our Cookies Policy in which you will also find how to configure your web browser for the use of cookies. More info